UNSPSC 51142515: Adrogolide

This classification denotes a dopamine agonist with the molecular formula C22H25NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YC3281G42A, chemically known as (5ar, 11bs) 4,5,5a,6,7,11b-hexahydro-2-propylbenzo(f)thienol(2,3c)quinoline-9,10-diol diacetate (ester) but generally known as adrogolide, which bears US NIH Compound Identifier 176876. Adrogolide comes in both base and hydrochloride forms.

The term ADROGOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule adrogolide under HS 29349990 and SITC 51579. As of Q4 2014, ADROGOLIDE remains the US FDA Preferred Term for this commodity. Adrogolide bears US NLM identifiers UMLS ID C0381061 and NCI Concept Code C73308. SMILES: CCCC1=CC2=C(S1)CNC3C2C4=CC(=C(C=C4CC3)OC(=O)C)OC(=O)C.

UNSPSC 51142515 Adrogolide is a Commodity code that covers pharmaceutical products, but recent state and local procurement activity under this code shows minimal direct relevance to adrogolide specifically. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement—naloxone systems, generic multi-source drugs, and over-the-counter products—indicating either misclassification in the underlying opportunity records or a functional mismatch between the narrow commodity definition and actual buying patterns. State and local issuing bodies pursuing pharmaceutical procurement include county health departments, state health and human services commissions, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work involves establishing supply contracts for finished pharmaceutical products with specific compliance requirements including FDA registration, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and contractual relationships with authorized wholesalers.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting a date discrepancy in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness of July 1, 2026. Vendors typically must maintain substantial insurance coverage, comply with federal environmental and security regulations, and demonstrate pricing flexibility across multiple net-price formats and wholesaler relationships.